Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC

19187

Studies in scope

all four open statuses

11790

Recruiting now

open to new participants

2028

Lead sponsors

across recruiting studies

Top sites

Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343

Trials with a site in Beijing

Status

Study

Lead sponsor

Phase

Enrol

Chinese sites

Start

Not yet open

Study of CM313 in Subject With IgA Nephropathy

NCT06830395IgA Nephropathy

DrugCM313

Keymed Biosciences Co.Ltd

Phase 2

106

Beijing

2025-09

Not yet open

A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension

NCT07152444Uncontrolled Hypertension

Qilu Pharmaceutical Co., Ltd.

Phase 1

Beijing

2025-09

Not yet open

A Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

NCT07106372Atopic Dermatitis

DrugStapokibatrt

Keymed Biosciences Co.Ltd

Phase 3

240

Beijing

2025-09

Recruiting

INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)

NCT07089862Unruptured Intracranial Aneurysm, Indobufen

Beijing Tiantan Hospital

Not applicable

2,500

Beijing

2025-08-31

Not yet open

Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis

NCT07131150Idiopathic Pulmonary Fibrosis (IPF)

Ruijin Hospital

Phase 2

Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing

2025-08-31

Not yet open

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07139548T2DM

DrugsRAY1225·Semaglutide

Guangdong Raynovent Biotech Co., Ltd

Phase 3

600

Beijing

2025-08-31

Not yet open

Early Blood Pressure Intervention After Coiling or Clipping for Subarachnoid Hemorrhage

NCT07149922Aneurysmal Subarachnoid Hemorrhage, Aneurysmal Subarachnoid Hemorrhage (aSAH)

Beijing Tiantan Hospital

Not applicable

750

Beijing

2025-08-31

Recruiting

Efficacy of a Health Empowerment Theory Based Health Information Literacy Promotion Intervention in Individuals With Metabolic Syndrome

NCT07096102Metabolic Syndrome (MetS)

Meihua Ji

Not applicable

310

Beijing

2025-08-31

Not yet open

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

NCT07159217Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors

DrugsDisitamab Vedotin·Camrelizumab·Toripalimab·Lenvatinib

Peking Union Medical College Hospital

Phase 2

Beijing

2025-08-30

Not yet open

A Placebo-controlled Trial of Fractional Flow Reserve-guided Percutaneous Renal Artery Stenting Among Atherosclerosis Renal-vascular Hypertension Patients

NCT07111442Renal Artery Stenosis Atherosclerotic, Secondary Hypertension Renal Arterial

DrugDopamine

Peking University First Hospital

Not applicable

200

Beijing

2025-08-30

Recruiting

Pulmonary Microbiota Changes and Clinical Outcomes in Neurosurgical ICU Patients With Artificial Airways

NCT07129174Ventilator-Associated Pneumonia (VAP), Intensive Care Unit (ICU) Patients, Microbiome Dysbiosis

Jian-Xin Zhou

Observational

220

Beijing

2025-08-30

Recruiting

Development and Validation of Delirium Recognition Using Computer Vision in Neuro-critical Patients

NCT07136207Delirium, Artificial Intelligence (AI)

Beijing Tiantan Hospital

Observational

1,000

Beijing

2025-08-30

Not yet open

Impact of Delayed Cord Clamping and Minimally Invasive Surfactant Administration on Outcomes in Premature Infants Less Than 30 Weeks Gestation

NCT07092319NRDS

Peking University Third Hospital

Observational

518

Beijing

2025-08-30

Recruiting

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

NCT07443397Whole-Brain Radiotherapy

DrugAnlotinib

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

134

Beijing

2025-08-29

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type

NCT07066826Alzheimer Dementia

DrugHuperzine A

Wanbangde Pharmaceutical Group Co., LTD

Phase 2/3

720

Beijing

2025-08-29

Recruiting

A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis

NCT07237568Ankylosing Spondylitis

DrugLNK01001

Lynk Pharmaceuticals Co., Ltd

Phase 3

352

Beijing

2025-08-29

Recruiting

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

NCT07165886Gastroenteropancreatic Neuroendocrine Tumors

DrugsSirolimus·Everolimus

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3

298

Beijing

2025-08-29

Recruiting

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

NCT07123129Advanced Malignancy

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

200

Beijing, Hangzhou

2025-08-28

Recruiting

Umbilical Cord Blood Megakaryocyte Injection (XJ-MK-002) for Cancer Therapy-Induced Thrombocytopenia (CTIT)

NCT07110090Thrombocytopenia, Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1

Beijing

2025-08-28

Recruiting

PVI Alone vs PVI and Linear Ablation for Persistent Atrial Fibrillation (PROMPT AF II)

NCT07106970Persistent Atrial Fibrillation

Boston Scientific Corporation

Not applicable

640

Beijing

2025-08-28

Recruiting

Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection

NCT07146100Chronic Hepatitis B

Ausper Biopharma Co., Ltd.

Observational

200

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou

2025-08-28

Active, closed

Adverse Events Among Hospitalized Patients in China

NCT07705204Adverse Event

Peking Union Medical College Hospital

Observational

2,807

Beijing

2025-08-28

Recruiting

A Study of LM-350 in Subjects With Advanced Solid Tumours

NCT07112222Malignant Tumors

LaNova Medicines Limited

Phase 1/2

Beijing

2025-08-28

Recruiting

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2

ADARx Pharmaceuticals, Inc.

Phase 3

Beijing, Harbin, Zhengzhou

2025-08-28

Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

DrugsLeucovorin·Adrucil·Tislelizumab·Capecitabine

BeOne Medicines

Phase 3

351

Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang

2025-08-27

Recruiting

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

NCT07147348Advanced Solid Tumor

DrugPumitamig

BioNTech SE

Phase 1/2

375

Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang

2025-08-27

Recruiting

A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS

NCT07084012Acute Ischemic Stroke AIS

DrugHUC-MSCs

Shenzhen Wingor Biotechnology Co., Ltd.

Phase 2

Beijing

2025-08-27

Not yet open

To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hallux Valgus Orthopedic Surgery

NCT07121023Postoperative Analgesia After Unilateral Hallux Valgus Correction Surgery

DrugTRD205

Beijing Tide Pharmaceutical Co., Ltd

Phase 1

Beijing

2025-08-26

Recruiting

Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma

NCT07754890Cutaneous T-cell Lymphoma (CTCL)

DrugsGolidocitinib·Chidamide

Peking Union Medical College Hospital

Phase 1/2

Beijing

2025-08-26

Recruiting

Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus

NCT07010835Systemic Lupus Erythematosus (SLE)

DrugYK012

Excyte Biopharma Ltd

Phase 1/2

189

Beijing

2025-08-25

Recruiting

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

NCT07594964Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)

DrugXH001

Shenzhen Xinhe Biomedical

Phase 1

Beijing

2025-08-25

Recruiting

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

NCT07383246Medullary Thyroid Carcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

150

Beijing

2025-08-25

Recruiting

Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens

NCT06923280Hepatitis B, Chronic

Huashan Hospital

Not applicable

Beijing, Shanghai

2025-08-25

Recruiting

LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft

NCT07773051Arteriovenous Graft

Longhua Hospital

Not applicable

326

Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang

2025-08-25

Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

NCT07096843Primary Membranous Nephropathy

DrugBudoprutug

Climb Bio, Inc.

Phase 2

Beijing, Shenzhen, Wuxi, Jinan, Yantai, Yibin

2025-08-25

Recruiting

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

NCT07099157Herpes Zoster

Peking University Third Hospital

Phase 4

140

Beijing

2025-08-25

Recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

NCT07616700IgA Nephropathy (IgAN)

DrugsHSK39297 200mgQD·HSK39297 300mgQD

Haisco Pharmaceutical Group Co., Ltd.

Phase 2

Beijing

2025-08-25

Not yet open

Child Vaccination Scheduling in China

NCT07141875Vaccination Behavior

Peking University

Observational

6,000

Beijing

2025-08-25

Not yet open

Arrhythmia Cohort Study

NCT07123896Arrhythmia

Beijing Anzhen Hospital

Observational

10,000

Beijing

2025-08-24

Recruiting

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

NCT07334483HCC

DrugsApatinib·Camrelizumab

GrandPharma (China) Co., Ltd.

Phase 2

120

Beijing, Nanjin, Shanghai

2025-08-22

Recruiting

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients

NCT07201467End-Stage Renal Disease Requiring Haemodialysis

DrugKN060

Suzhou Alphamab Co., Ltd.

Phase 1/2

Beijing

2025-08-22

Recruiting

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

NCT07154706Non-small Cell Lung Cancer (NSCLC)

DrugTaletrectinib

Nuvation Bio Inc.

Phase 3

180

Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang

2025-08-21

Recruiting

A Study of HB0056 in Adult Participants With Moderate to Severe Asthma

NCT07899996Asthma

DrugHB0056

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 1/2

160

Beijing

2025-08-21

Recruiting

AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

NCT06959524Coronary Arterial Disease (CAD), de Novo Lesions in Native Coronary Arteries

Boston Scientific Corporation

Not applicable

1,616

Beijing, Beijin, Guangzhou, Wuhan, Xi'an

2025-08-21

Recruiting

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

NCT07082686Relapsed or Refractory Mantle Cell Lymphoma (MCL)

DrugICP-248

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 2

Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou

2025-08-21

Recruiting

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)

DrugsEnlicitide Decanoate·Enlicitide

Merck Sharp & Dohme LLC

Phase 2/3

153

Beijing, Guangzhou, Shanghai, Hangzhou

2025-08-21

Recruiting

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

NCT07111832PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

DrugsTrastuzumab Rezetecan·Adebrelimab·Toripalimab·Paclitaxel

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

400

Beijing, Shanghai

2025-08-20

Not yet open

Clinical Observation and Risk Factor Analysis of the Incidence of Postoperative PTSD in Children

NCT07088692PTSD

JianHao Zhang

Observational

400

Beijing

2025-08-20

Recruiting

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020

NCT07230652Schizophrenia, Alzheimer's Disease Psychosis

DrugLY03020

Luye Pharma Group Ltd.

Phase 1

Beijing

2025-08-20

Recruiting

PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT07133750CRC (Colorectal Cancer)

DrugPumitamig

Biotheus Inc.

Phase 2

100

Beijing, Guangzhou, Harbin, Wuhan, Changchun, Jinan, Shanghai, Chengdu

2025-08-19

Recruiting

The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

NCT07065968Immune Thrombocytopenia (ITP)

DrugsTeriflunomide·Dexamethasone

Peking University People's Hospital

Phase 2

132

Beijing

2025-08-19

Recruiting

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

NCT07059650Diffuse Large B-Cell Lymphoma

DrugsR-GemOx·Birelentinib·R-Chop

Dizal Pharmaceuticals

Phase 1/2

150

Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Taiyuan

2025-08-19

Active, closed

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

DrugsTarlatamab·Etoposide·Durvalumab·Carboplatin

Amgen

Phase 3

350

Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai

2025-08-18

Recruiting

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

NCT07280494CD7+ T-ALL/LBL

Peking University People's Hospital

Phase 1

Beijing

2025-08-18

Recruiting

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

NCT07097818Type 1 Diabetes

Second Xiangya Hospital of Central South University

Not applicable

400

Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang

2025-08-18

Not yet open

XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer

NCT07114666Pancreatic Cancer

DrugXH001

Peking Union Medical College Hospital

Not applicable

Beijing

2025-08-18

Recruiting

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976Autoimmune Haemolytic Anaemia

DrugRilzabrutinib

Sanofi

Phase 3

Beijing, Chengde, Guangzhou, Hohhot, Nanchang, Suzhou, Tianjin, Wuhan

2025-08-18

Recruiting

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

NCT07143929CD7 Positive R/R PTCL

DrugCar-T

Peking University People's Hospital

Phase 1

Beijing

2025-08-18

Recruiting

Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants

NCT07182656Rheumatoid Arthritis (RA)

Yi Fang

Phase 1

Beijing

2025-08-18

Recruiting

Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease Who Are Still Symptomatic After Optimal Medical Treatment

NCT07041359Coronary Arterial Disease (CAD)

DrugCompound Danshen Dripping Pills

China National Center for Cardiovascular Diseases

Phase 4

120

Beijing

2025-08-18

Active, closed

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

NCT07081022B-cell Non-Hodgkin's Lymphoma

DrugsJS203·Gemcitabine and oxaliplatin·Lenalidomide

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

180

Beijing

2025-08-17

Recruiting

Biomarker-Integrated Digital Guidance for Early Alzheimer's Detection (BRIDGE-AD): A Nationwide Multicenter Study

NCT07284264Dementia

Xuanwu Hospital, Beijing

Observational

6,000

Beijing, Hainan, Ningxiang, Shenyang, Shenzhen, Yichun

2025-08-15

Recruiting

Clinical Application of Wearable Ultrasound Sensors

NCT07009873DVT - Deep Vein Thrombosis, POCUS

Chinese PLA General Hospital

Observational

300

Beijing

2025-08-15

Recruiting

Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation

NCT07158710Malignant Brain Tumors

DrugHSK42360

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

159

Beijing, Fuzhou, Guangzhou, Changchun, Shanghai

2025-08-15

Not yet open

Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification

NCT07111429Complication,Postoperative, Stoma

Peking University Cancer Hospital & Institute

Observational

5,000

Beijing

2025-08-15

Recruiting

Multi-omics Studies of Primary Aldosteronism

NCT07111351Primary Aldosteronism

Peking University First Hospital

Observational

400

Beijing

2025-08-15

Recruiting

Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke

NCT07026318Acute Ischemic Stroke

DrugTirofiban

Beijing Anzhen Hospital

Not applicable

716

Beijing

2025-08-15

Recruiting

Research on Identifying Critical Surgical Anatomy in Cholecystectomy Videos Based on Deep Learning

NCT07158372Cholecystectomy, Surgical Video Identification

Chinese Academy of Sciences

Observational

200

Zhengzhou, Beijing, Shanghai

2025-08-15

Recruiting

Construction and Validation of a Predictive Model for the Efficacy of Different Biologics in Inflammatory Bowel Disease

NCT07181525Inflamatory Bowel Disease

Peking University First Hospital

Observational

200

Beijing

2025-08-15

Recruiting

pCAD-POAF 3 Year Follow-up

NCT07146061Coronary Artery Disease, Atrial Fibrillation

China National Center for Cardiovascular Diseases

Observational

430

Beijing

2025-08-15

By invitation

Research on NI-FAPI-04 for the Treatment of Hypoxic and Fibroblast Activation Protein Related Tumors

NCT07822347Tumor

Peking Union Medical College Hospital

Phase 1/2

Beijing

2025-08-15

Recruiting

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

NCT07095023Breast Cancers

DrugsPertuzumab/Trastuzumab·Paclitaxel

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not applicable

112

Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen

2025-08-15

Recruiting

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

NCT07023315Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

DrugCadonilimab

Akeso

Phase 3

760

Beijing, Fuzhou, Shijiazhuang, Harbin, Shanghai, Tianjin

2025-08-14

Recruiting

A Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer

NCT07777211Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas

DrugGKL-006

Beijing Gene Key Life Technology Co., Ltd

Phase 1/2

Beijing

2025-08-14

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang

2025-08-14

Active, closed

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

NCT06994650Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

DrugHRS9531

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

144

Beijing

2025-08-13

Not yet open

Prognostic Model for MASLD Related Cirrhosis

NCT07082751Metabolic Dysfunction Associated Steatotic Liver Disease, Compensated Cirrhosis

Beijing Friendship Hospital

Observational

228

Beijing, Tianjin

2025-08-13

Recruiting

Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

NCT07193459Type 2 Diabetes

DrugHDM1002

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

360

Beijing

2025-08-12

Recruiting

Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function

NCT07144098Obesity/Overweight

DrugBofanglutida

Gan & Lee Pharmaceuticals.

Phase 1

Beijing

2025-08-12

Active, closed

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

NCT07246889Chronic Hepatitis B

DrugAHB-137

Ausper Biopharma Co., Ltd.

Phase 3

577

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Foshan, Guangzhou

2025-08-12

Recruiting

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT07460362MCL, Relapsed or Refractory Mantle Cell Lymphoma (MCL)

DrugsGlofitamab·Lenalidomide

Peking University Third Hospital

Phase 2

Beijing

2025-08-11

Recruiting

A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors

NCT07105215Solid Tumors

RemeGen Co., Ltd.

Phase 1/2

312

Beijing, Fuzhou, Xiamen, Guilin, Nanning, Harbin, Luoyan, Luoyang

2025-08-11

Active, closed

A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07021976Obstructive Hypertrophic Cardiomyopathy

DrugHRS-1893

Shandong Suncadia Medicine Co., Ltd.

Phase 3

228

Beijing

2025-08-11

Recruiting

Shame-Focused Cognitive Behavioral Therapy For Reducing Suicide Risk In Adolescent Psychiatric Inpatients (SF-CBT)

NCT07294001Adolescent Suicide, Suicidal Ideation, Suicidal Behavior, Shame

Peking University

Not applicable

Beijing

2025-08-10

Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

NCT07152639Tuberculosis

Chengdu CoenBiotech Co., Ltd

Phase 3

1,784

Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu

2025-08-09

Recruiting

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT07239947Atopic Dermatitis

DrugBBT001

Bambusa Therapeutics

Phase 1

Hefei, Wuhu, Beijing, Guangzhou, Changsha, Wuxi, Zhenjiang, Nanchang

2025-08-09

Recruiting

Effectiveness of an AI-Enabled Stratified Management System for Premature Coronary Artery Disease

NCT07031531Premature Coronary Heart Disease

China National Center for Cardiovascular Diseases

Not applicable

4,900

Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou

2025-08-08

By invitation

A Randomized Trial of Six-Channel RF Ablation System for Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease

NCT07130955Hypertension, CKD - Chronic Kidney Disease

Shanghai Golden Leaf MedTec Co. Ltd

Not applicable

236

Beijing

2025-08-08

Active, closed

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma

DrugPirtobrutinib

Eli Lilly and Company

Phase 2

Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan

2025-08-07

Active, closed

A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus

NCT07055386Type 2 Diabetes Mellitus (T2DM)

DrugsGZR102·Bofanglutida

Gan & Lee Pharmaceuticals.

Phase 2

Beijing

2025-08-07

Active, closed

Parent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy After Completion of the BaxPA Main Study.

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

212

Beijing, Changsha, Chengdu, Chongqing, Nanjing, Shanghai, Tianjin, Wuhan

2025-08-07

By invitation

"Real-world Assessment of BP Control in Patients With Hypertension by the Netrod RDN System" - REACH-RDN

NCT07273877Hypertension

Shanghai Golden Leaf MedTec Co. Ltd

Observational

1,000

Beijing

2025-08-07

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua

2025-08-06

Recruiting

Interventional Left Ventricular Assist System for PCI in CHIP Patients

NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices

Suzhou Hengruihongyuan Medical Technology Co. LTD

Not applicable

286

Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang

2025-08-06

Recruiting

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

NCT07088068Type 1 Diabetes Mellitus

DrugsTzield·Teplizumab

Sanofi

Phase 3

723

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot

2025-08-06

Recruiting

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

NCT07103668Gastric Adenocarcinoma

Suzhou Immunofoco Biotechnology Co., Ltd

Phase 3

150

Beijing

2025-08-06

Recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms

Eli Lilly and Company

Phase 1

421

Beijing, Tianjin

2025-08-06

Recruiting

Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation

NCT06871228Atrial Fibrillation (AF)

Beijing Anzhen Hospital

Not applicable

4,100

Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan

2025-08-05

Active, closed

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

NCT07029451Infertility

Ferring Pharmaceuticals

Observational

2,549

Hefei, Ma’anshan, Beijing, Chaoyang, Xicheng, Guangzhou, Shantou, Nanning

2025-08-05

Recruiting

Study on the Improvement of Metabolic Indicators in Type 1 Diabetes Patients

NCT07144696Type 1 Diabetes Mellitus

Peking University First Hospital

Not applicable

150

Beijing

2025-08-05

Active, closed

Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma

NCT07081633Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 2

114

Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing

2025-08-05

Recruiting

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)

Shanghai Henlius Biotech

Phase 2

Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing

2025-08-05

Recruiting

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596Atrial Fibrillation (AF)

China National Center for Cardiovascular Diseases

Early Phase 1

3,160

Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu

2025-08-05

Recruiting

Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis

NCT07042126Dermatitis, Atopic

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

180

Beijing, Jinhua, Nanchang

2025-08-05

Recruiting

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965Breast Cancer

DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant

Pfizer

Phase 3

400

Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin, Wuhan

2025-08-05

Active, closed

The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease

NCT07080775Parkinson's Disease

XellSmart Therapeutics (Shanghai) Co., Ltd.

Phase 1/2

Beijing

2025-08-05

Recruiting

A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

NCT07060989Advanced Solid Tumors

Nutshell Therapeutics (Shanghai) Co., LTD.

Phase 1/2

220

Beijing, Guangzhou, Nanchang, Shanghai, Xi'an

2025-08-04

Recruiting

Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation

NCT06952842Retinitis Pigmentosa

DrugZVS203e

Chigenovo Co., Ltd

Phase 1/2

Beijing

2025-08-04

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07005102Non-Squamous Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib·Pemetrexed·Cisplatin

AbbVie

Phase 2/3

854

Beijing, Fuzhou, Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu

2025-08-03

Recruiting

Novel Biomarkers and Postoperative Kidney Injury in Radical Nephrectomy

NCT07088874Nephrectomy, Acute Kidney Injury, Biomarker

Peking University First Hospital

Observational

Beijing

2025-08-02

Recruiting

Real World Evidence Study of SYN023 in Children Exposed to Rabies

NCT07327307Rabies Post-exposure Prophylaxis

Synermore Biologics (Suzhou) Co., Ltd.

Observational

232

Beijing, Shenzhen, Changsha, Hengyang, Nanchang

2025-08-02

Recruiting

Investigator Initiated Trial of Galcanezumab Treatment in Alzheimer's Disease

NCT07323927Alzheimer Disease

DrugGalcanezumab

Xuanwu Hospital, Beijing

Early Phase 1

Beijing

2025-08-01

Recruiting

31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum

NCT07912086Cardiomyopathies, Heart Failure

Chinese Academy of Medical Sciences, Fuwai Hospital

Observational

1,000

Beijing

2025-08-01

Recruiting

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

NCT07257510Mantle Cell Lymphoma (MCL), POZ

DrugsLisaftoclax·Orelabrutinib·Pomalidomide

Peking University Third Hospital

Not applicable

Beijing

2025-08-01

Recruiting

Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia

NCT07468383Symptomatic Bradycardia, Autonomic Nervous System Diseases

Beijing Anzhen Hospital

Not applicable

188

Beijing

2025-08-01

Recruiting

Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

NCT06674460Cerebral Small Vessel Disease, Ischemic Stroke

DrugEdaravone dexborneol sublingual

Peking Union Medical College Hospital

Phase 3

600

Beijing

2025-08-01

Recruiting

Environmental Pollutants and Neurological Disorders

NCT07140601Cerebrovascular Disorders, Brain Tumours, Alzheimer Dementia

Beijing Tiantan Hospital

Observational

500

Beijing

2025-08-01

Active, closed

Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH

NCT07204041Langerhans Cell Histiocytosis (LCH)

DrugsThalidomide·Selinexor·Dexamethasone

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-08-01

Recruiting

Pegmolesatide Treatment for Anemia in Patients Undergoing Long-term Dialysis

NCT07045155Dialysis; Complications, Chronic Kidney Disease 5D, Renal Anemia of Chronic Kidney Disease, Renal Anaemia

Chinese PLA General Hospital

Phase 4

240

Beijing

2025-08-01

Recruiting

68Ga-NYM096 PET/CT in Various Kinds of Cancer

NCT07144748Cancer

Peking Union Medical College Hospital

Not applicable

120

Beijing

2025-08-01

Not yet open

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study2

NCT07034807Diabetic Kidney Disease (DKD)

Liu Hongfang

Not applicable

228

Beijing, Guangzhou, Changchun, Tianjin

2025-08-01

Not yet open

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

NCT07090538Neuroblastoma

DrugEliglustat

Chinese PLA General Hospital

Early Phase 1

Beijing

2025-08-01

Not yet open

YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1

NCT07032116Diabetic Kidney Disease (DKD)

Liu Hongfang

Observational

4,472

Beijing, Guangzhou, Changchun, Tianjin

2025-08-01

Not yet open

A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen

NCT07099794Biliary Tract Cancer (BTC)

DrugsNaliri·Liposomal Irinotecan·Lenvatinib·Capecitabine

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-08-01

Active, closed

JiGenerations Health Cohort Study：Parental Exposure and Intergenerational Health in China

NCT07514377Environmental Exposure, Fertility, Health Problems in Pregnancy, Adverse Pregnancy Outcomes

National Research Institute for Family Planning, China

Observational

100,000

Beijing

2025-08-01

By invitation

Digital Phenotyping of High-Risk Chronic Ventilator-Dependent Patients

NCT07656155Ventilator Dependency

China-Japan Friendship Hospital

Observational

30,500

Beijing

2025-08-01

Not yet open

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms

NCT07077330Relapsed or Refractory Plasma Cell Neoplasms

Chinese PLA General Hospital

Early Phase 1

Beijing

2025-08-01

Not yet open

A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.

NCT07083375Extensive Small Cell Lung Cancer

DrugCarboplatin

Zhijie Wang

Phase 2

Beijing

2025-08-01

Not yet open

Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions

NCT07023575Interstitial Lung Abnormalities

China-Japan Friendship Hospital

Observational

100,000

Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang

2025-08-01

Recruiting

Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors.

NCT06173219Advanced Solid Tumor

China-Japan Friendship Hospital

Phase 1/2

Beijing

2025-08-01

Recruiting

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

NCT06994507Chemotherapy-induced Peripheral Neuropathy (CIPN)

Qilu Pharmaceutical Co., Ltd.

Phase 3

352

Beijing

2025-08-01

Not yet open

Precise Phenotyping Classification in Atrial Fibrillation

NCT07044011Atrial Fibrillation

China National Center for Cardiovascular Diseases

Observational

1,000

Beijing

2025-08-01

Recruiting

CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism

NCT04211181Venous Thromboembolic Disease, Pulmonary Embolism, Venous Thromboembolism, Deep Venous Thrombosis

China-Japan Friendship Hospital

Not applicable

5,800

Beijing

2025-08-01

Recruiting

Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD

NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)

Xueyan Zhao

Observational

12,154

Zhengzhou, Shenyang, Beijing

2025-08-01

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou

2025-08-01

Recruiting

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

NCT06970912Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer

DrugDalpiciclib

Peking University People's Hospital

Phase 2

393

Beijing

2025-08-01

Not yet open

A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia

NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms

Shanghai Huilun Pharmaceutical Co., Ltd.

Phase 3

728

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou

2025-08

Not yet open

Improvement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise

NCT07049731Sarcopenia

Weiwei Ma

Not applicable

224

Beijing

2025-08

Not yet open

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

NCT07079579Renal Anemia in Non-dialysis Chronic Kidney Disease

DrugEnarodustat

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 4

120

Beijing

2025-08

Not yet open

A Study of Collagen Scaffold for the Repair of Elbow Cartilage Injury

NCT07149896Cartilage Defect, Elbow Injury

Beijing Jishuitan Hospital

Phase 3

Beijing

2025-08

Not yet open

A Clinical Study to Evaluate the Safety and Pharmacokinetics of Topical RSS0393 Ointment in Children and Adolescents With Plaque Psoriasis

NCT07102888Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents

DrugRSS0393

Jiangsu HengRui Medicine Co., Ltd.

Phase 2

Beijing

2025-08

Not yet open

A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

NCT07083739Primary Immune Thrombocytopenia

DrugTQB3473

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2

320

Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang

2025-08

Not yet open

KANGFUPEN Liquid Dressing for Chronic Radiation-Induced Rectal Injury

NCT07065175Chronic Radiation-induced Proctitis

Peking Union Medical College Hospital

Phase 2

Beijing

2025-08

Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors

DrugsPanitumumab·Pembrolizumab

Amgen

Phase 1

434

Beijing, Chongqing, Jinan

2025-07-31

Recruiting

Marshall Vein Ethanol Infusion in Addition to Pulsed Electric Field Ablation Versus Pulsed Electric Field Ablation Alone for Paroxysmal Atrial Fibrillation

NCT07095959Atrial Fibrillation (AF)

Beijing Anzhen Hospital

Not applicable

340

Beijing

2025-07-31

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou

2025-07-31

Recruiting

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant

NCT07007143Mitral Regurgitation

DrugClopidogrel

Chinese Academy of Medical Sciences, Fuwai Hospital

Phase 4

1,032

Beijing

2025-07-31

Recruiting

An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT07879885Moderate-to-severe Plaque Psoriasis

Hansoh BioMedical R&D Company

Phase 2

390

Beijing

2025-07-31

Not yet open

Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor

NCT06998173Advanced Solid Tumors

Danatlas Pharmaceuticals Co., Ltd

Phase 1

228

Beijing

2025-07-31

Recruiting

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

NCT07058662DMD

Belief BioMed (Beijing) Co., Ltd

Phase 1/2

Beijing

2025-07-31

Not yet open

A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC

NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112

DrugsPenpulimab·Ivonescimab

Yang Fan, MD

Phase 2

164

Beijing, Changsha, Shanghai, Xi’an, Hangzhou

2025-07-31

Recruiting

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)

DrugsHDM2005·Rituximab Biosimilar·Doxorubicin·Prednisone

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha

2025-07-30

Recruiting

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111Esophageal Squamous Cell Carcinoma

DrugsIfinatamab Deruxtecan·Sacituzumab tirumotecan·Leucovorin·Adrucil

Merck Sharp & Dohme LLC

Phase 1/2

298

Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang

2025-07-30

Active, closed

A Food Effect Study of LY03020 in Healthy Subjects

NCT07292233Schizophrenia, Alzheimer's Disease Psychosis

DrugLY03020

Luye Pharma Group Ltd.

Phase 1

Beijing

2025-07-30

Recruiting

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

NCT07047014Stroke, Ischemic, Medium Vessel Occlusions

DrugTenecteplase

Beijing Tiantan Hospital

Phase 3

596

Beijing, Jiuquan, Shijiazhuang, Jiyuan, Lingbao, Nantong, Hangzhou

2025-07-30

Recruiting

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

NCT06897046Non-small Cell Lung Cancer (NSCLC), II-IIIB

DrugsLenvatinib·Carboplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-07-30

Not yet open

Deep Cervical Lymphatic Venous Anastomosis in the Treatment of Alzheimer's Disease (CLEAN-AD Registry)

NCT07058129Alzheimers Disease

Beijing Tiantan Hospital

Observational

814

Beijing

2025-07-30

Not yet open

The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

NCT07064889Immune Thrombocytopenia

DrugsUpadacitinib·Dexamethasone

Peking University People's Hospital

Phase 2

132

Beijing

2025-07-30

Recruiting

The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation：a Pilot Study

NCT07387952Constipation - Functional, Fecal Microbiota Transplantation (FMT), Chronic Constipation

Peking Union Medical College Hospital

Not applicable

Beijing

2025-07-30

Recruiting

Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

NCT07079475Non-Small Cell Lung Cancer

DrugsDZD6008·Sunvozertinib·Osimertinib

Dizal Pharmaceuticals

Phase 1/2

220

Beijing, Guangzhou, Harbin, Changsha, Nanjing, Shengyang, Jinan, Shanghai

2025-07-30

Not yet open

A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors

NCT07046780Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced

PENG YUAN

Observational

Beijing

2025-07-30

Not yet open

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

NCT06772233Metastatic Gastrointestinal Stromal Tumors (GIST)

DrugsEnvafolimab·Regorafenib

Peking University

Phase 2

100

Beijing

2025-07-30

Recruiting

TQB2922 and TAS-102 Tablets for Injection With or Without Bevacizumab in Chemotherapy-failed RAS/BRAF Wild-type Advanced Colorectal Cancer

NCT07044908RAS/BRAF Wild Type Colorectal Cancer

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1/2

Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Meizhou, Shantou, Nanning

2025-07-30

Recruiting

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

NCT06911502Follicular Lymphoma

DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine

Celgene

Phase 3

400

Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou

2025-07-28

Active, closed

A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)

NCT07073417Obesity, Weight Management

DrugsEcnoglutide·Semaglutide

Hangzhou Sciwind Biosciences Co., Ltd.

Phase 2

163

Beijing

2025-07-28

Not yet open

Phase I/II Study of SCTB39G in Advanced Solid Tumours

NCT07077252Advanced Malignant Solid Tumor

Sinocelltech Ltd.

Phase 1/2

Beijing

2025-07-28

By invitation

Ureteroscopy Combined With Negative Pressure Sheath Treatment of Kidney Stones

NCT06938113Kidney Calculi

Peking University First Hospital

Observational

115

Beijing

2025-07-28

Recruiting

Repetitive Transcranial Magnetic Stimulation and Postoperative Neurocognitive Recovery

NCT06482749Older Patients, Cognitive Impairment, Repetitive Transcranial Magnetic Stimulation, Delayed Neurocognitive Recovery

Peking University First Hospital

Not applicable

568

Beijing, Shenzhen, Xi'an

2025-07-28

Recruiting

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

NCT06838832Non-hodgkin Lymphoma,B Cell

DrugsFludarabine·Cyclophosphamide

Chinese PLA General Hospital

Phase 1/2

Beijing

2025-07-27

Recruiting

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer

DrugMRG007

ArriVent BioPharma, Inc.

Phase 1

572

Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong

2025-07-25

Recruiting

TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer

NCT07047365HER2-positive Advanced Breast Cancer

DrugsTQB2930·Trastuzumab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

416

Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen

2025-07-25

Recruiting

Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

NCT07060456Type 2 Diabetes

DrugHRS9531

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

300

Beijing

2025-07-25

Recruiting

A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity

NCT06974851Bstructive Sleep Apnea (OSA) and Obesity

DrugHRS9531

Fujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

140

Beijing

2025-07-25

Recruiting

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

NCT07039578Primary Light-Chain Amyloidosis

DrugCM336

Keymed Biosciences Co.Ltd

Phase 2

Beijing, Tianjin

2025-07-25

Active, closed

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433Atherosclerotic Cardiovascular Disease, Overweight, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

12,800

Bengbu, Beijing, Guangzhou, Huizhou, Yulin, Qinhuangdao, Shijiazhuang, Harbin

2025-07-25

Recruiting

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

NCT07213765Mycobacterium Avium Complex Pulmonary Disease

DrugsAzithromycin·Ethambutol·Linezolid·Rifampicin

Bin Cao

Phase 4

188

Hefei, Beijing, Guangzhou, Nanchang, Shanghai

2025-07-24

Recruiting

a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）

NCT07128797NAFLD (Non-alcoholic Fatty Liver Disease), NASH (Nonalcoholic Steatohepatitis)

Tasly Biopharmaceuticals Co., Ltd.

Phase 1

Beijing, Guangzhou, Datong, Tianjin, Wenzhou

2025-07-24

Recruiting

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

NCT06757634Breast Cancer

DrugsGedatolisib·Ribociclib·Palbociclib·Letrozole

Celcuity Inc

Phase 3

1,180

Beijing, Quanzhou, Luoyang, Xinxiang, Zhengzhou, Changsha, Shaoyang, Nanjing

2025-07-24

Recruiting

Prevention of Recurrence With Cordyceps Sinensis in Mycobacterium Avium Complex Pulmonary Disease

NCT07174076Mycobacterium Avium Complex Pulmonary Disease

Bin Cao

Phase 4

300

Hefei, Beijing, Guangzhou, Nanchang, Shanghai

2025-07-24

Recruiting

A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema

NCT06807268Eczema

DrugAbrocitinib

Pfizer

Phase 3

150

Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou

2025-07-24

Recruiting

Short-term Bactericidal Effect of Contezolid in MAC-PD

NCT07084402Mycobacterium Avium Complex Pulmonary Disease

DrugsAzithromcyin·Ethambutol·Linezolid·Rifampicin

Bin Cao

Phase 4

188

Beijing, Nanchang

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Hefei, Beijing, Fuzhou, Guangzhou, Huizhou, Nanning, Harbin, Luoyang

2025-07-23

Recruiting

A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors

NCT07083323Advanced Solid Tumor

Sichuan Huiyu Pharmaceutical Co., Ltd

Phase 1/2

262

Beijing

2025-07-22

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian

2025-07-22

Recruiting

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

NCT07069062Solid Tumor

Sichuan Huiyu Pharmaceutical Co., Ltd

Phase 1/2

261

Beijing

2025-07-21

Recruiting

MRgLITT for mTLE: A PROBE Trial

NCT06720922Temporal Lobe Epilepsy (TLE)

Beijing Tiantan Hospital

Not applicable

120

Beijing

2025-07-21

By invitation

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

NCT06910072Triple-Negative Breast Cancer (TNBC), Neoadjuvant Therapy

DrugsPaclitaxel Polymeric Micelles·Carboplatin

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3

Beijing

2025-07-21

Recruiting

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

NCT07060807Breast Neoplasms

DrugsPatritumab deruxtecan·Pegylated liposomal doxorubicin·Abraxane·Xeloda

Merck Sharp & Dohme LLC

Phase 3

1,000

Hefei, Beijing, Chongqing, Wanzhou, Fujian, Guangzhou, Jiangmen, Nanning

2025-07-21

By invitation

Exploratory Trial of VR Intervention on Neuroplasticity in Older Adults With Cognitive Frailty

NCT07183033Cognitive Frailty

Peking Union Medical College

Not applicable

Beijing

2025-07-21

Recruiting

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT

NCT07126782AML (Acute Myelogenous Leukemia), AML

Institute of Hematology & Blood Diseases Hospital, China

Early Phase 1

Beijing

2025-07-20

Recruiting

REFINE-HCM: Intramyocardial Septal Radiofrequency Ablation for Obstructive Hypertrophic Cardiomyopathy

NCT07006493Hypertrophic Cardiomyopathy, Obstructive

SuZhou Sinus Medical Technologies Co.,Ltd

Not applicable

124

Beijing, Hangzhou

2025-07-20

Not yet open

Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma

NCT07091227Gastric or Gastroesophageal Junction Adenocarcinoma

DrugsIvonescimab·Capecitabine·Oxaliplatin

Peking Union Medical College Hospital

Phase 2

Beijing

2025-07-20

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants

NCT07005713Chronic Spontaneous Urticaria

DrugTacabrutideg

BeOne Medicines

Phase 1

Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou

2025-07-19

Recruiting

Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial

NCT07118345Stroke, Ischemic, Cerebral Edema

Xuanwu Hospital, Beijing

Not applicable

380

Beijing, Shandong

2025-07-19

Recruiting

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

NCT06929273Bipolar Disorder Type I With Mania

DrugsValproate·Lamotrigine·Lithium·KarXT

Bristol-Myers Squibb

Phase 3

450

Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin

2025-07-18

Active, closed

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm

DrugBesremi

PharmaEssentia

Phase 3

160

Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing

2025-07-18

Recruiting

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089Solid Tumors

DrugsDB-1305/BNT325·Pumitamig

DualityBio Inc.

Phase 2

750

Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou

2025-07-18

Recruiting

A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

NCT07071337Metastatic Breast Cancer

DrugsSacituzumab tirumotecan·Nab-paclitaxel·Capecitabine·Paclitaxel

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3

430

Beijing, Guangzhou

2025-07-18

Recruiting

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

NCT06824168Acute Myeloid Leukemia, Leukemia

DrugQuizartinib

Daiichi Sankyo

Phase 2

130

Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao

2025-07-18

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Beijing, Changchun, Changzhi, Chengdu, Fuzhou, Hangzhou, Kunming, Qingdao

2025-07-17

Recruiting

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT07039669Pulmonary Disease, Chronic Obstructive (COPD)

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Phase 3

594

Beijing, Shenzhen, Nanjing, Hangzhou

2025-07-16

Recruiting

Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients

NCT07296627Newly Diagnosed Multiple Myeloma (NDMM)

Peking University People's Hospital

Observational

500

Beijing

2025-07-16

By invitation

A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy

NCT07135219Immunoglobulin A Nephropathy (IgAN)

DrugCizutamig

Peking University First Hospital

Early Phase 1

Beijing

2025-07-16

Recruiting

A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

NCT06997497Colon Adenocarcinoma, Rectal Adenocarcinoma

DrugsLeucovorin/levofolinate calcium·Bevacizumab biosimilar·Calderasib·Mvasi

Merck Sharp & Dohme LLC

Phase 3

477

Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Xiamen, Guangzhou, Shenzhen

2025-07-16

Recruiting

A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

NCT06963827Kidney Disease

DrugMezagitamab

Takeda

Phase 3

347

Beijing, Changping, Xiamen, Guangdong, Guangzhou, Shenzhen, Changsha, Baotou

2025-07-15

Recruiting

A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors

NCT07043751Advanced Malignant Tumors

DrugTQB6411

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 1

216

Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha

2025-07-15

By invitation

Spontaneous Breathing Mode: A Risk for Hypoxemia During OLV?

NCT07494006Lung Cancer, OLV, Hypoxemia During Surgery

Peking University People's Hospital

Observational

Beijing

2025-07-15

Active, closed

The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations

NCT07035652Chronic Obstructive Pulmonary Disease

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 1

Beijing

2025-07-15

Not yet open

A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

NCT07087041Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease

Beijing Friendship Hospital

Observational

735

Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Zhuhai, Guiyang, Shiyan

2025-07-15

Active, closed

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

NCT06963710Chronic Hepatitis B Infection

DrugALG-000184

Aligos Therapeutics

Phase 2

200

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Nanjing, Shanghai

2025-07-15

Not yet open

Calcium Channel Blocker Amlodipine for Endometrial Cancer Therapy

NCT06942377Endometrial Cancer

DrugAmlodipine

Peking University People's Hospital

Phase 2

140

Beijing

2025-07-15

Recruiting

Efficacy and Safety of Surgical Treatment for Type IVa CBD

NCT07036848Choledochal Cyst

Beijing Tsinghua Chang Gung Hospital

Observational

1,500

Beijing

2025-07-14

Recruiting

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

NCT07559864GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation

DrugsEnvafolimab·Regorafenib

Jian Li

Phase 2

100

Beijing

2025-07-14

Recruiting

Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta

NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section

The Third Affiliated Hospital of Guangzhou Medical University

Not applicable

600

Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing

2025-07-12

Active, closed

Telitacicept for PGNMID: A Single-Arm Study

NCT07111338Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits

DrugTelitacicept

Peking University First Hospital

Phase 2

Beijing

2025-07-12

Active, closed

Efficacy of Rescue Stenting/Angioplasty After Failed Thrombectomy for Acute Large Intracranial Vascular Occlusion

NCT07026344Acute Ischemic Stroke

Beijing Anzhen Hospital

Not applicable

312

Beijing

2025-07-12

Recruiting

Study of GV20-0251 in Participants With Solid Tumor Malignancies

NCT07070518Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma

DrugGV20-0251

GV20 Therapeutics

Phase 1/2

350

Beijing, Shanghai

2025-07-11

Recruiting

This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

NCT06862206Chronic Obstructive Pulmonary Disease

AstraZeneca

Observational

1,000

Anhui, Anning, Beijing, Binzhou, Changzhou, Fenyang, Guangdong, Guangzhou

2025-07-11

Not yet open

Longitudinal Observational Study on Immune Thrombocytopenia

NCT07068425Immune Thrombocytopenia (ITP)

Peking University People's Hospital

Observational

2,000

Beijing

2025-07-10

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

NCT07011732Alzheimer Disease

DrugsKarX-EC·KarXT

Bristol-Myers Squibb

Phase 3

426

Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai

2025-07-10

Recruiting

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

NCT07097935Advanced Clear Cell Renal Cell Carcinoma

DrugsHS-10516·Lenvatinib

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1/2

104

Beijing

2025-07-10

Recruiting

A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors

NCT06953323Advanced Solid Tumor

DrugsWJB001·Niraparib·Paclitaxel·Bevacizumab

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Phase 1/2

Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou

2025-07-10

Recruiting

Study on the Safety and Efficacy of Domestic Single-Port Robot-Assisted Metabolic Bariatric Surgery.

NCT07335731Obesity, Robot Surgery

China-Japan Friendship Hospital

Not applicable

Beijing

2025-07-10

Recruiting

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

NCT07186621Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE

DrugSintilimab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 3

286

Beijing

2025-07-10

Recruiting

Application of the CD73-Targeted Probe ⁶⁸Ga-DOTA-mPNE PET/CT Imaging in the Diagnosis of Malignant Tumors

NCT07023640Malignant Neoplasms of Brain

Peking Union Medical College Hospital

Not applicable

Beijing

2025-07-10

Recruiting

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

NCT07070323T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia, T-cell Malignancies

Beijing GoBroad Hospital

Phase 1/2

Beijing, Shanghai, Chengdu

2025-07-09

Recruiting

Teneteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅳ

NCT06414499Minor Ischemic Stroke

DrugsRhTNK-tPA·Clopidogrel

Beijing Tiantan Hospital

Phase 3

1,386

Beijing

2025-07-09

Active, closed

A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine

NCT07047638Skin Quality Improvement

Galderma R&D

Not applicable

171

Beijing

2025-07-09

Recruiting

A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors

NCT07032077Solid Tumors

DrugHRS-7058

Shandong Suncadia Medicine Co., Ltd.

Phase 2

100

Beijing

2025-07-09

Recruiting

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa

NCT06932003Hidradenitis Suppurativa (HS)

DrugLT-002-158

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Phase 1/2

Beijing

2025-07-08

Recruiting

Endobronchial Silicone Valve for Patients With Emphysema

NCT07097896Emphysema

China-Japan Friendship Hospital

Not applicable

147

Beijing

2025-07-08

Recruiting

Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy

NCT07823049Pancreatic Cancer

DrugXNW28012

Evopoint Biosciences Inc.

Phase 3

226

Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang

2025-07-08

Recruiting

QA108 Phase III Study in Subjects With Intermediate AMD

NCT07189169Intermediate Age-Related Macular Degeneration

Smilebiotek Zhuhai Limited

Phase 3

400

Beijing

2025-07-08

Recruiting

MITRIS China Post Market Clinical Follow-up (PMCF) Study

NCT07059793Mitral Valve Replacement

Edwards Lifesciences

Observational

250

Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan

2025-07-08

Active, closed

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556Metastatic Hormone-sensitive Prostate Cancer

DrugsLuxdegalutamide·Abiraterone·Enzalutamide

Novartis Pharmaceuticals

Phase 2

168

Beijing

2025-07-07

Recruiting

A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

NCT07068165IgG4 Related Disease

DrugsPrednisone·Lenalidomide

Peking Union Medical College Hospital

Phase 2/3

198

Beijing

2025-07-07

Recruiting

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

NCT07008976Metastatic Breast Cancer

DrugsTQB2102·Trastuzumab emtansine

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

246

Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang

2025-07-07

Recruiting

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

NCT06930794Non-Small Cell Lung Cancer

DrugVebreltinib

Beijing Pearl Biotechnology Limited Liability Company

Phase 3

300

Beijing, Guangzhou

2025-07-07

Not yet open

AI-Driven Early Warning System for Perioperative Risks in Acute Hemorrhagic Stroke

NCT06998082Acute Hemorrhagic Stroke

Beijing Tiantan Hospital

Observational

1,533

Beijing

2025-07-06

Recruiting

Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery

NCT07048002Silent Brain Infarction, Neurocognitive Disorders, Cardiac Surgery, Neuroprotective

Chinese Academy of Medical Sciences, Fuwai Hospital

Not applicable

912

Beijing, Wuhan

2025-07-06

Active, closed

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 4

Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot

2025-07-04

Recruiting

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients

NCT07177482Craniopharyngioma

Deling Li

Not applicable

Beijing

2025-07-04

Recruiting

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy

NCT07021963Hypertrophic Cardiomyopathy

DrugHRS-1893

Shandong Suncadia Medicine Co., Ltd.

Phase 2

300

Beijing

2025-07-04

Active, closed

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07047118Prostatic Cancer, Castration-Resistant

DrugsLuxdegalutamide·Lu-PSMA

Novartis Pharmaceuticals

Phase 2

138

Beijing

2025-07-03

Recruiting

Effect of Balloon Angioplasty vs Stenting Following Residual Stenosis After Endovascular Treatment of Intracranial Atherosclerotic Acute Ischemic Stroke

NCT07026331Acute Ischemic Stroke, Intracranial Atherosclerosis ICAS

Beijing Anzhen Hospital

Not applicable

486

Beijing

2025-07-03

Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

NCT06859762Advanced Solid Tumor

DrugBevacizumab

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 1

630

Beijing, Guangzhou, Harbin, Nanchang, Shenyang, Jinan, Shanghai, Tianjin

2025-07-02

Recruiting

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

NCT07177352Alzheimers Disease

Hoffmann-La Roche

Phase 3

80,000

Beijing, Xuzhou, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing

2025-07-02

Not yet open

A Study Evaluating the Diagnostic Performance of OCS in the Differential Diagnosis of Endometriosis vs. Endometriosis-Associated Ovarian Cancer

NCT07029659Endometriosis, Endometriosis-Associated Ovarian Carcinoma

Peking Union Medical College Hospital

Observational

336

Beijing

2025-07-01

Not yet open

Daratumumab for Familial Cerebral Cavernous Malformations: A Single-Arm Safety and Efficacy Study

NCT07026604Cavernous Malformation, Cerebral

DrugDaratumumab

Beijing Tiantan Hospital

Early Phase 1

Beijing

2025-07-01

Recruiting

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

NCT07058948Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2

Beijing, Cangzhou, Tianjin

2025-07-01

Recruiting

The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine

NCT07023926Menstrually Related Migraine, Electroacupuncture

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

Beijing

2025-07-01

Not yet open

Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases

NCT07051070Anti-Vimentin Antibody-associated Diseases, Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies

Xuanwu Hospital, Beijing

Phase 4

Beijing

2025-07-01

By invitation

Effect of Perioperative Dexmedetomidine on Chronic Post-Surgical Pain

NCT06849466Chronic Post-Surgical Pain

DrugDexmedetomidine

Peking Union Medical College Hospital

Phase 4

364

Beijing

2025-07-01

Recruiting

IVUS-FFR Accuracy for Coronary Stenosis

NCT07446023Percutaneous Coronary Intervention, Intravenous Ultrasound, Coronary Physiology

China National Center for Cardiovascular Diseases

Not applicable

292

Beijing

2025-07-01

Not yet open

hUC-MSC-sEV-001 Nasal Drops for Neurodegenerative Diseases

NCT06607900Alzheimer Disease, Parkinson Disease, Lewy Body Dementia, Multiple System Atrophy

Xuanwu Hospital, Beijing

Phase 1

120

Beijing

2025-07-01

Recruiting

The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly

NCT07057973Ferric Carboxymaltose

DrugFerric Carboxymaltose

Xuanwu Hospital, Beijing

Not applicable

100

Beijing

2025-07-01

Recruiting

Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

NCT07185841Wet Age-related Macular Degeneration (AMD)

Fujian Haixi Pharmaceuticals Co., Ltd.

Phase 1/2

198

Beijing

2025-07-01

Active, closed

AI-Based Risk Factor Analysis and Prediction Model of MACE in Elderly Hip Fracture Patients Postoperatively

NCT07709377Hip Fracture, MACE, Elderly, Perioperative Complications

Beijing Anzhen Hospital

Observational

600

Beijing

2025-07-01

Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277Prostate Cancer

DrugsAAA817·ARPI

Novartis Pharmaceuticals

Phase 3

940

Fuzhou, Guangzhou, Wuhan, Nanjing, Shenyang, Chengdu, Hangzhou, Beijing

2025-07-01

By invitation

68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses

NCT07101900Clear Cell Renal Cell Carcinoma

Peking Union Medical College Hospital

Phase 2

100

Beijing

2025-07-01

Recruiting

Association of Genetic Variants With Myopia

NCT07030153Myopia

Beijing Visionly Plus Eye Hospital

Observational

1,000

Beijing

2025-07-01

Not yet open

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

NCT07024147B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma, Marginal Zone B Cell Lymphoma

DrugsFludarabine·Cyclophosphamide

Peking University Cancer Hospital & Institute

Phase 1

Beijing

2025-07-01

Not yet open

Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP

NCT07057778Immune Thrombocytopenia (ITP)

DrugsIguratimod·Rituximab

Peking University People's Hospital

Phase 2

120

Beijing

2025-07-01

Recruiting

Dexamethasone Palmitate for PONV After Open Surgery

NCT06997419Postoperative Nausea and Vomiting, Dexamethasone Palmitate, Open Surgery

DrugsDexamethasone palmitate·Dexamethasone

Beijing Tiantan Hospital

Not applicable

500

Beijing

2025-07-01

Recruiting

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations

NCT07037238Vascular Malformations

DrugEverolimus

Xuanwu Hospital, Beijing

Phase 2

Beijing

2025-07-01

Not yet open

Basilar Artery Occlusion Chinese Endovascular Trial in Patients With Large Core Infarct

NCT07046299Basilar Artery Occlusion, Ischemic Stroke, Large Core Infarct

Capital Medical University

Not applicable

314

Beijing

2025-07-01

Recruiting

Alzheimer's Disease Multinuclear Imaging Neuro-Enhanced Resolution (AD-MINER)

NCT07089303Alzheimer Disease, Mild Cognitive Impairment Due to Alzheimer's Disease

Chinese PLA General Hospital

Observational

750

Beijing

2025-07-01

Recruiting

Exploration of the Safety and Efficacy of T-DXd Concurrent With Brain Radiotherapy in Patients With Brain Metastases HER2-positive/HER2-low Advanced Breast Cancer

NCT07117864Breast Cancer

QIAO LI

Not applicable

Beijing

2025-07-01

Recruiting

AI-Guided Hematoma Aspiration vs. Conservative Treatment for Spontaneous ICH

NCT07077343Intracerebral Hemorrhage

Xiaolei Chen

Not applicable

680

Beijing

2025-07-01

Recruiting

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

NCT06828042Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome, ANCA Associated Vasculitis (AAV)

Peking University Third Hospital

Phase 1/2

Beijing

2025-07-01

Recruiting

Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease

NCT07031687Alzheimer Disease

Xuanwu Hospital, Beijing

Not applicable

1,200

Sanya, Beijing

2025-07-01

Recruiting

Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)

NCT07111260End Stage Renal Disease on Dialysis

Peking University People's Hospital

Not applicable

Beijing

2025-07-01

Not yet open

Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage

NCT06711302Subarachnoid Hemorrhage, Cerebrovascular Disorders, Brain Diseases, Stroke

Beijing Tiantan Hospital

Not applicable

500

Beijing

2025-07-01

Active, closed

Oral Ondansetron to Improve Patient Experience of Unsedated Esophagogastroduodenoscopy Pilot Study

NCT07264738Esophagogastroduodensocopy (EGD) Procedure

Peking Union Medical College Hospital

Phase 4

Beijing

2025-07-01

Not yet open

The Study on the Effectiveness of [68Ga]Ga-HBED-CC-DiAsp PET/CT in Calculating GFR and Predicting Residual Renal Function After Partial Nephrectomy

NCT06973798Kidney Neoplasms / Surgery, Glomerular Filtration Rate, Positron-Emission Tomography(PET)

Luo Yaping

Not applicable

Beijing

2025-07-01

Recruiting

Rectal NSAIDs With/Without PD Stent for PEP Prevention

NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement

DrugNSAIDs

Air Force Military Medical University, China

Not applicable

1,278

Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an

2025-07-01

Recruiting

VIM+PTT MRgFUS for PD

NCT07044973Parkinson Disease

Chinese PLA General Hospital

Not applicable

Beijing

2025-07-01

Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

NCT07359040Non-Small Cell Lung Cancer, Neoadjuvant Therapy, PD-1 Inhibitors, Immunotherapy

DrugsVenetocalx·Ivonescimab

Peking University People's Hospital

Observational

Beijing

2025-07-01

Recruiting

The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

NCT07212933Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy

DrugTrifluridine/Tipiracil

Chinese PLA General Hospital

Phase 2

Beijing

2025-07-01

Recruiting

Safety and Efficacy of Ventricular Irrigation for Ventriculitis

NCT06358209Central Nervous System Infections

RenJi Hospital

Not applicable

310

Hefei, Wuhu, Beijing, Fuzhou, Guangzhou, Shenzhen, Zhongshan, Harbin

2025-07-01

Not yet open

Evaluating AI and Human Expert Decisions in Colorectal Cancer

NCT07045207Colorectal Cancer

Peking University Cancer Hospital & Institute

Observational

1,500

Beijing

2025-07-01

Recruiting

PET/MR Multimodal Quantitative Analysis of CBF and CMRGlc in Cerebral Ischemia

NCT07079345PET/MR, Stroke Ischemic

Xuanwu Hospital, Beijing

Observational

200

Beijing

2025-07-01

Not yet open

Glymphatic Function and White Matter Integrity in Cerebral Venous Disorders

NCT07072663Cerebral Venous Sinus Thrombosis

Xuanwu Hospital, Beijing

Observational

149

Beijing

2025-07

Not yet open

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

NCT07007936Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee

Shenyang Sunshine Pharmaceutical Co., LTD.

Phase 2

Beijing

2025-07

Not yet open

Phase I/II Clinical Study of HRS-1738 for the Diagnosis of Prostate Cancer Patients

NCT07056439PET Imaging in Patients With Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2

Beijing

2025-07

Not yet open

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

NCT06998719Non-small Cell Lung Cancer Stage III, Borderline Resectable Carcinoma

DrugDurvalumab

Bi Nan

Phase 2

Beijing

2025-07

Recruiting

A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

NCT06962865Non-Small Cell Lung Cancer

DrugsFurmonertinib Mesilate·Furmonertinib

RemeGen Co., Ltd.

Phase 2

Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou

2025-06-30

Not yet open

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

NCT07004075Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration

DrugLuvometinib

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 3

102

Beijing

2025-06-30

Recruiting

Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)

NCT07509749GVHD, Acute, Stem Cell Transplant Complications

DrugMethylprednisolone

Daihong Liu

Phase 2

Beijing

2025-06-30

By invitation

Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)

NCT07023965Peripheral Arterial Disease(PAD), Arterial Occlusive Disease, Arteriosclerosis Obliterans, Thromboangiitis Obliterans

Beijing Northland Biotech. Co., Ltd.

Observational

542

Beijing, Chifeng, Dalian, Hangzhou, Xi'an

2025-06-30

By invitation

Extubation Safety Via Microstream EtCO₂ (IPI) Monitoring

NCT06975553Hypoxemia

Chinese PLA General Hospital

Not applicable

632

Beijing

2025-06-30

Recruiting

Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer

NCT07116213Endometrial Cancer, Hypofractionated Dose, Radiotherapy, Adjuvant, Side Effects

Xiaorong Hou

Not applicable

Beijing

2025-06-30

By invitation

Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics of NTB003 in Healthy Participants

NCT07182552TED

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 1

Beijing

2025-06-30

Recruiting

Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease

NCT07657624Coronary Heart Disease, Cognitive Impairment, Mild

Beijing Anzhen Hospital

Observational

2,352

Beijing

2025-06-30

Not yet open

PCT Guided Antibiotics Use in Critically Ill Adult Patients in China

NCT06945510Sepsis

China-Japan Friendship Hospital

Not applicable

800

Beijing

2025-06-30

Not yet open

The Safety, Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease

NCT07028632Parkinson Disease (PD)

iRegene Therapeutics Co., Ltd.

Phase 2

Beijing

2025-06-30

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms

DrugsEpirubicin·Adriamycin·Xeloda·Paraplatin

Merck Sharp & Dohme LLC

Phase 3

2,400

Hefei, Beijing, Xiamen, Guangzhou, Jiangmen, Liuzhou, Nanning, Xingtai

2025-06-30

Recruiting

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

NCT07012304Chronic Graft Versus Host Disease

DrugGecacitinib Hydrochloride

Yujun DONG

Phase 1/2

Beijing

2025-06-30

Recruiting

Study on the Trans-Carotid Artery Occlusion Shunt System

NCT06924593Revascularization, Carotid Artery Stenosis, Carotid Artery Diseases

Shenzhen Wecan Medical Technology Co.,Ltd

Not applicable

162

Beijing

2025-06-30

Recruiting

Development, Application, and Mechanistic Investigation of a Novel Minimally-Invasive Bidirectional Epidural Cerebellar Stimulation Technique for Cerebellar Cognitive Affective Syndrome

NCT07166432Cerebellar Atrophy, Etiology, Physiopathology

Peking University First Hospital

Observational

200

Beijing

2025-06-28

Recruiting

Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis

NCT07079423AL Amyloidosis

DrugTeclistamab

Peking Union Medical College Hospital

Phase 2

Beijing

2025-06-28

Recruiting

Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

NCT07067905Clear Cell Renal Cell Carcinoma and Glioblastoma

Chinese PLA General Hospital

Early Phase 1

Beijing

2025-06-27

Recruiting

Prospective Single-Arm Clinical Trial of GO Regimen for HLH.

NCT07339345Lymphohistiocytosis, Hemophagocytic

DrugGolidocitinib

Beijing Friendship Hospital

Phase 2/3

Beijing

2025-06-27

Recruiting

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

NCT07082738Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Phase 2

987

Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou

2025-06-27

Active, closed

A Prospective, Single-center, Open-label Study of Inhaled BMD003 (CFTR mRNA) in Chinese Adults With Cystic Fibrosis

NCT06963008Cystic Fibrosis (CF), Gene Therapy

DrugBMD003

Peking Union Medical College Hospital

Early Phase 1

Beijing

2025-06-27

Recruiting

Evaluating the Efficacy and Safety of Contact Lens Lubricant in Rigid Gas Permeable Corneal Contact Lens Wearers

NCT07091825Myopia

Avizor SA

Not applicable

152

Beijing, Tianjin

2025-06-27

Recruiting

Evidence-based Practice in the Management of Gastric Tube Placement in Children

NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy

Children's Hospital of Fudan University

Not applicable

2,750

Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan

2025-06-26

Recruiting

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity

DrugMaridebart cafraglutide

Amgen

Phase 3

5,056

Hefei, Beijing, Guangzhou, Haikou, Qinhuangdao, Shijiazhuang, Daqing, Harbin

2025-06-25

Active, closed

A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD

NCT06843408Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 1/2

Beijing, Chengdu, Chongoing, Guangzhou, Hangzhou, Shanghai, Tianjin, Wuhan

2025-06-25

Recruiting

Dexamethasone Palmitate for PONV After Craniotomy

NCT06988124Postoperative Nausea and Vomiting

DrugsDexamethasone palmitate·Dexamethasone

Beijing Tiantan Hospital

Not applicable

500

Beijing

2025-06-25

Recruiting

Phase I Study of MT1011 Injection in Healthy Subjects

NCT07024160Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Phase 1

Beijing

2025-06-25

Active, closed

Hyperkalemia Quality Improvement Program (HK-QIP) Study

NCT06884267Hyperkalemia

AstraZeneca

Not applicable

1,000

Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang

2025-06-25

Recruiting

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

NCT07033819Ovarian Cancer

DrugApatinib

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-06-25

Recruiting

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

NCT07003074Breast Cancer

DrugsTQB2102·Pertuzumab·Trastuzumab

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Phase 3

642

Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou

2025-06-23

Recruiting

Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

NCT07050641Advanced Malignant Solid Tumor

Sinocelltech Ltd.

Phase 1/2

110

Beijing

2025-06-23

Recruiting

Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer

NCT06926140Lung Cancers

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

240

Hefei, Beijing, Changsha

2025-06-21

Not yet open

A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma

NCT07014540Neuroendocrine Carcinomas (NEC)

DrugsIrinotecan Hydrochloride Liposome·Adrucil

Beijing GoBroad Hospital

Phase 4

Beijing

2025-06-20

Active, closed

A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

NCT06937749Metabolic Dysfunction-associated Steatohepatitis (MASH)

DrugMazdutide

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

181

Beijing

2025-06-20

Recruiting

PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma

NCT07018518Hepatocellular Carcinoma, Adult

DrugAnti-PD1

Chinese PLA General Hospital

Phase 1

Beijing

2025-06-20

Recruiting

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels: A Prospective, Multicenter, Double-Blind, Placebo-Controlled Randomized Trial

NCT06014060Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent, Dual Antiplatelet Therapy

China National Center for Cardiovascular Diseases

Not applicable

3,300

Beijing

2025-06-20

Recruiting

A Study in Children With Achondroplasia

NCT07301463Achondroplasia

Abbisko Therapeutics Co, Ltd

Observational

260

Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou

2025-06-20

Recruiting

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

NCT07108127Rectal Cancer, HER2-positive

DrugXelox

Peking Union Medical College Hospital

Phase 2

Beijing

2025-06-20

Recruiting

A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection

NCT07764679Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)

HTA Co., Ltd.

Phase 3

400

Beijing

2025-06-20

Recruiting

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

NCT07008885Acute Lymphocytic Leukemia

DrugsFludarabine·Cyclophosphamide

Chinese PLA General Hospital

Phase 1/2

Beijing

2025-06-20

Recruiting

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

NCT07009002B Cell Lymphoma

DrugsFludarabine·Cyclophosphamide

Chinese PLA General Hospital

Phase 1/2

Beijing

2025-06-20

Recruiting

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

NCT07078591Acute Myeloid Leukemia

DrugsGpbmc·Ara-C·Daunorubicin·Cytarabine

Beijing 302 Hospital

Phase 2

Beijing

2025-06-20

Recruiting

Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS

NCT07238686Myelodysplastic Syndromes

DrugsGpbmc·Decitabine·Azacitidine·Venetoclax

Beijing 302 Hospital

Phase 2

Beijing

2025-06-20

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

981

Haikou, Changsha, Chengdu, Beijing, Changchun, Chongqing, Dongguan, Fuyang

2025-06-20

Recruiting

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

NCT06947980Atopic Dermatitis

DrugCM512

Keymed Biosciences Co.Ltd

Phase 2

200

Beijing

2025-06-19

Recruiting

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

NCT06991257Heart Failure

DrugPF-07328948

Pfizer

Phase 2

620

Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an

2025-06-19

Recruiting

A PAN-USR TB Multi-Center Trial

NCT06905522Pulmonary Tuberculosis

DrugsPretomanid·Sitafloxacin·Bedaquiline·Pyrazinamide

Shenzhen Third People's Hospital

Phase 3

610

Beijing, Shenzhen, Ürümqi

2025-06-18

Recruiting

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

NCT06992713Advanced Solid Tumor

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Phase 1

Nanjing, Beijing, Shanghai

2025-06-18

Recruiting

Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage

NCT07026994Cerebral Amyloid Angiopathy, Intracerebral Hemorrhage Lobar

DrugColchicine

Huashan Hospital

Phase 2

Beijing, Chengdu, Shanghai

2025-06-18

Recruiting

Clinical Implications of Three-vessel Ultrasonic Flow Ratio Measurement in Patients With Coronary Artery Disease

NCT06822894Coronary Artery Disease (CAD)

China National Center for Cardiovascular Diseases

Observational

494

Beijing

2025-06-18

Active, closed

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial

NCT06941792Coronary Heart Disease

DrugInclisiran sodium

Novartis Pharmaceuticals

Phase 4

1,590

Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang

2025-06-17

Active, closed

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744Ulcerative Colitis

DrugsRisankizumab·Vedolizumab

AbbVie

Phase 3

573

Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha

2025-06-17

Recruiting

A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients

NCT06985368Solid Tumor Malignancy

Shanghai Institute Of Biological Products

Phase 1

156

Beijing

2025-06-16

Recruiting

Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

NCT07259889Advanced Solid Tumors (Phase 1)

Guangzhou Xiling Biotechnology Co., Ltd.

Phase 1

Beijing

2025-06-16

Active, closed

RB001 Gene Therapy Study in Children With SHANK3-related Phelan-McDermid Syndrome (PMS)

NCT07014020Phelan-McDermid Syndrome, SHANK3 Haploinsufficiency

Peking University First Hospital

Phase 1

Beijing

2025-06-16

Recruiting

Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer

NCT07029269Gastric Adenocarcinoma, Laparoscopic Gastrectomy, Complications

Zuoyi Jiao

Phase 3

454

Beijing, Fuzhou, Lanzhou, Zhejiang, Xi'an

2025-06-16

Recruiting

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

NCT06893016Obesity

DrugRAY1225

Guangdong Raynovent Biotech Co., Ltd

Phase 3

640

Beijing

2025-06-15

Not yet open

The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

NCT07013838Takayasu Arteritis (TAK)

DrugsDeucravacitinib·Adalimumab

Chinese SLE Treatment And Research Group

Phase 4

Beijing

2025-06-15

Not yet open

Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV

NCT06986018Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis

DrugRD06

Peking University People's Hospital

Early Phase 1

Beijing

2025-06-14

Recruiting

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis

DrugRavulizumab

Alexion Pharmaceuticals, Inc.

Phase 3

Beijing, Shanghai

2025-06-14

Recruiting

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features

DrugKarXT

Bristol-Myers Squibb

Phase 3

274

Beijing, Wuhan, Changsha, Jining Shi, Tianjin

2025-06-13

Recruiting

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis

Alebund Pharmaceuticals

Phase 3

264

Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi

2025-06-13

Recruiting

A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT07010263Small Cell Lung Cancer

DrugIvonescimab

Akeso

Phase 3

560

Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen

2025-06-13

Recruiting

Phase I Study of XTL6001 Injection in Healthy and Obese Subjects

NCT07205432Weight Management in Adult Patients With Obesity or Overweight

Shanghai Xitaili Biomedicine Technology co., Ltd.

Phase 1

Beijing

2025-06-13

Recruiting

STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant

NCT06901466Mitral Regurgitation

DrugClopidogrel

Chinese Academy of Medical Sciences, Fuwai Hospital

Phase 4

880

Beijing

2025-06-13

Recruiting

A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery

NCT06674252Lung Cancers

Peking University Cancer Hospital & Institute

Not applicable

174

Beijing

2025-06-13

Recruiting

Finerenone Therapy for Pediatric HSPN With Mild Proteinuria

NCT07315191Henoch Schönlein Purpura Nephritis

DrugsACEI/ARB·Finerenone

Capital Institute of Pediatrics, China

Phase 4

116

Beijing

2025-06-13

Recruiting

Qingre Huatan Formula for the Prevention of Early Neurological Deterioration in Acute Ischemic Stroke

NCT06857487Acute Ischemic Stroke

Dongzhimen Hospital, Beijing

Phase 1/2

Beijing

2025-06-13

Recruiting

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

NCT07327034Hepatocellular Carcinoma (HCC)

DrugABSK-011

Abbisko Therapeutics Co, Ltd

Phase 2

141

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guilin, Liuzhou, Nanning

2025-06-13

Recruiting

Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors

NCT06926751Solid Tumors, Children, Adolescent, Chemotherapy Induced Neutropenia

DrugsTelpegfilgrastim·Filgrastim

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

132

Beijing

2025-06-12

Active, closed

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

NCT07029555Rheumatoid Arthritis

DrugPIT565

Novartis Pharmaceuticals

Phase 1

Beijing

2025-06-12

Recruiting

Changes in Rimazolen Dosage in Patients With Insomnia Under Intravenous Anesthesia

NCT07028190Insomnia, Digestive Endoscopy

Beijing Tiantan Hospital

Observational

840

Beijing

2025-06-12

Recruiting

Changes in Etomidate Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia

NCT07028177Insomnia, Digestive Endoscopy

Beijing Tiantan Hospital

Observational

840

Beijing

2025-06-12

Recruiting

A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2

NCT06931028Sleep Apnea, Obstructive, Obesity

DrugMazdutide

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

260

Beijing

2025-06-12

Recruiting

NWRD09 for HPV-16 Related Cervical HSIL

NCT07047989High-grade Squamous Intraepithelial Lesion (HSIL)

DrugNWRD09

Newish Biotech (Wuxi) Co., Ltd.

Phase 1

Beijing

2025-06-12

Recruiting

Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy

NCT07014202Non-Small Cell Lung Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

224

Beijing

2025-06-11

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin

2025-06-11

Recruiting

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

NCT06783647Advanced Solid Tumour

DrugsLBL-024·Pemetrexed·Docetaxel·Paclitaxel

Nanjing Leads Biolabs Co.,Ltd

Phase 2

250

Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Guilin, Nanning, Harbin

2025-06-11

Not yet open

Telitacicept for the Treatment of Refractory RA

NCT07008196Rheumatoid Arthritis (RA)

DrugTelitacicept

Chinese SLE Treatment And Research Group

Phase 4

Beijing

2025-06-10

Recruiting

Clinical Study to Evaluate the Efficacy and Safety of Mesenchymal Stromal Cells (Amimestrocel ) in Patients With Acute Kidney Injury

NCT06954740Acute Kidney Injury

DrugAmimestrocel

Chinese PLA General Hospital

Phase 2

Beijing

2025-06-10

Not yet open

Safety and Effectiveness of Unilateral MR-Guided Focused Ultrasound Thalamotomy for Essential Tremor

NCT07006740Essential Tremor

meishanshan

Observational

100

Beijing

2025-06-10

Recruiting

Non-pharmacologial, Non-invassive Intervention Before Cardiac Surgery: a Randomized Controlled Trial

NCT06791551Cardiac Surgery

China National Center for Cardiovascular Diseases

Not applicable

200

Beijing

2025-06-10

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shantou

2025-06-10

Recruiting

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844Advanced Solid Tumors, Advanced Breast Cancer

DrugFulvestrant

Ensem Therapeutics

Phase 1/2

233

Beijing, Fuzhou, Guangzhou, Shandong, Shanghai

2025-06-10

Not yet open

Azole Susceptibility and Resistance Mechanisms Surveys in Pathogenic Fungi by the CARST-fungi (2023-2024)

NCT06969703Fungal Disease

Peking University First Hospital

Observational

Beijing

2025-06-10

Recruiting

Efficacy and Safety Evaluation of CICAPLAST BAUME B5+ on Rosacea Accompanied by Sensitive Skin

NCT07106957Erythematous Telangiectatic Rosacea

Beijing Sino-German Union Cosmetic Institute Co., Ltd.

Not applicable

Beijing

2025-06-10

Recruiting

Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma

NCT07014150Hepatocellular Carcinoma Resectable

DrugsIparomlimab and Tuvonralimab·Lenvatinib

Peking Union Medical College Hospital

Phase 2

Beijing

2025-06-10

Recruiting

Temporal Interference for Essential Tremor

NCT07016425Essential Tremor

Liankun_Ren

Not applicable

Beijing

2025-06-09

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei

2025-06-09

Recruiting

A Clinical Study of GenSci134 in Healthy Adults and Adult Growth Hormone Deficiency(AGHD)

NCT07016802Safety, Tolerability, Adult Growth Hormone Deficiency

DrugsGenSci134·Recombinant Human Growth Hormone·Norditropin

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1

Beijing

2025-06-09

Recruiting

Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease

NCT06969807Diabetic Kidney Disease (DKD)

DrugAmimestrocel

Chinese PLA General Hospital

Phase 2

120

Beijing

2025-06-09

Recruiting

A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT06907615Non Small Cell Lung Cancer

DrugsHLX43 2·HLX43 1

Shanghai Henlius Biotech

Phase 2

243

Beijing

2025-06-09

Recruiting

A Real-World Study on Ultrasound-Based Screening and Integrated Therapeutic Strategies for Patients With Concomitant Coronary and Cervicocephalic Artery Stenosis

NCT07034157Coronary Artery Disease, Carotid Artery Stenosis, Cerebrovascular Disorders

Beijing Anzhen Hospital

Observational

1,000

Beijing

2025-06-09

Recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

NCT06808984Agitation, Alzheimer Disease

DrugIrafamdastat

Celgene

Phase 2

120

Hefei, Beijing, Wuhan, Nanjing, Shanghai Shi, Hangzhou

2025-06-09

Recruiting

A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs

NCT07069569Chronic Hepatitis B

DrugsHepatitis B Vaccine·Peg-IFNα·AHB-137

Ausper Biopharma Co., Ltd.

Phase 2

200

Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zunyi, Wuhan, Changchun

2025-06-08

Recruiting

A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults

NCT07149831Prostate Cancer

Sinotau Pharmaceutical Group

Phase 1

Beijing

2025-06-07

Active, closed

A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases

NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN

DrugSGB-9768

Suzhou Sanegene Bio Inc.

Phase 2

Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan

2025-06-06

Recruiting

Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy

NCT07257471Lung Cancer (NSCLC)

Beijing Haidian Hospital

Observational

Beijing

2025-06-06

Active, closed

Shared Medical Appointment for COPD Patients (SMA-COPD)

NCT07128745Chronic Obstructive Pulmonary Disease, COPD

Peking University Third Hospital

Not applicable

280

Beijing

2025-06-05

Recruiting

Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

NCT06917664Coronary Artery Disease, Ischemic Mitral Regurgitation, Angiotensin Receptor/Neprilysin Inhibitor

DrugSacubitril / Valsartan

China National Center for Cardiovascular Diseases

Phase 4

220

Beijing

2025-06-05

Recruiting

Timing and Outcomes of Recovery After intraCerebral Hemorrhage

NCT07166146Intracerebral Haemorrhage, Intracerebral Hemorrhage

Xuanwu Hospital, Beijing

Observational

500

Beijing

2025-06-04

Recruiting

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07038343Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers

Avenzo Therapeutics, Inc.

Phase 1/2

480

Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan

2025-06-04

Recruiting

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis

NCT06931990Atopic Dermatitis (AD)

DrugLT-002-158

Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

Phase 1/2

Beijing

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha

2025-06-04

Active, closed

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

NCT06872125Dravet Syndrome

DrugZorevunersen

Stoke Therapeutics, Inc

Phase 3

170

Beijing, Guangzhou, Wuhan

2025-06-04

Recruiting

A Trial of HRS-5965 Capsule in Primary IgA Nephropathy

NCT07014826Primary IgA Nephropathy

DrugHRS-5965

Chengdu Suncadia Medicine Co., Ltd.

Phase 3

378

Beijing

2025-06-04

Recruiting

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06852222Leukemia, Myeloid, Acute

DrugsBleximenib·Azacitidine·Venetoclax

Janssen Research & Development, LLC

Phase 3

600

Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan

2025-06-04

Not yet open

A Population-based Cohort of Osteoarthritis: the Tsinghua University Tiantongyuan Community Osteoarthritis Study

NCT07006701Osteoarthritis

Beijing Tsinghua Chang Gung Hospital

Observational

4,000

Beijing

2025-06-03

Recruiting

FAP-targeted PET/NIR in Lung Malignant Tumors

NCT07498933Non-Small Cell Lung Cancer, PET/CT, Neoadjuvant Therapy

Peking University People's Hospital

Observational

200

Beijing

2025-06-03

Recruiting

EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders

NCT07450391Epstein-Barr Virus-Associated Lymphoproliferative Disorders, EBV-Positive Lymphoma

Daihong Liu

Phase 1/2

Beijing

2025-06-01

Recruiting

Safety and Effectiveness of No-touch Technique for Ascending Aorta in MICS-CABG

NCT07172620Coronary Artery Bypass Grafting, Off-pump Coronary Artery Bypass, Minimally Invasive Cardiac Surgery, Coronary Arterial Disease (CAD)

Peking University Third Hospital

Observational

260

Beijing

2025-06-01

Recruiting

Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer

NCT07015138Prostate Cancer, Oligometastatic Prostate Cancer

Peking University First Hospital

Not applicable

390

Beijing

2025-06-01

Recruiting

68Ga-PFA2 PET Imaging for the Diagnosis of Annexin A2-Positive Tumors

NCT07331532Breast Neoplasms、Lung Neoplasms、Pancreatic Neoplasms

Peking University First Hospital

Observational

Beijing

2025-06-01

Recruiting

Indomethacin vs Diclofenac for Preventing PEP

NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin

DrugsIndomethacin·Diclofenac

Air Force Military Medical University, China

Not applicable

4,050

Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City

2025-06-01

Not yet open

Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer

NCT07004712Small Cell Lung Cancer

DrugAdebelizumab

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-06-01

Recruiting

A Clinical Prediction Model for Surgical Site Infection After Central Nervous System Tumor Surgery

NCT07378683Surgical Site Infection (SSI), Central Nervous System Tumor

Ming Yang

Not applicable

500

Beijing

2025-06-01

Recruiting

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

NCT07053462End-Stage Renal Disease, End Stage Renal Disease on Dialysis, End Stage Renal Disease With Renal Transplant, Kidney Transplant Rejection

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2

Beijing

2025-06-01

Recruiting

Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer

NCT07034742Gastric Adenocarcinoma

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Early Phase 1

136

Beijing

2025-06-01

By invitation

A Clinical Study on the Use of the Sentinel Cerebral Protection Device During TAVR for the Prevention of Procedure-Related Stroke

NCT07045233Stroke, Transcatheter Aortic Valve Replacement (TAVR), Aortic Stenosis Treated With TAVI

China National Center for Cardiovascular Diseases

Observational

200

Beijing

2025-06-01

Recruiting

Correlation Study Between SMA Blood Flow Reactivity and Acute Gastrointestinal Injury in Critically Ill Patients

NCT07001943Intestinal Ischemia, Critical Illness, Enteral Nutrition Feeding, Hemodynamics

Peking Union Medical College Hospital

Observational

Beijing

2025-06-01

Recruiting

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

NCT07022964T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)

Beijing GoBroad Hospital

Phase 1/2

Beijing, Shanghai

2025-06-01

Recruiting

Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

NCT07368634Epstein-Barr Virus Infection, Post-Transplant Lymphoproliferative Disorder

Daihong Liu

Phase 1/2

Beijing

2025-06-01

Active, closed

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

NCT07094464TP53-mutated MDS and AML, Allogeneic Hematopoietic Stem Cell Transplantation

Daihong Liu

Phase 1

Beijing

2025-06-01

Recruiting

Prediction Model of Colorectal Adenoma Recurrence-Carcinogenesis Risk With TCM-WM Multimodal Feature Fusion

NCT07611266Colorectal Cancer Control and Prevention

Beijing Friendship Hospital

Observational

3,000

Beijing

2025-06-01

Recruiting

CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection

NCT07053488Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure

AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC

Phase 1/2

Beijing

2025-06-01

Recruiting

Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

NCT07040098Locally Advanced Rectal Cancer (LARC)

DrugSintilimab

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

228

Beijing, Shenzhen

2025-06-01

Recruiting

Prospective Multicenter Registry Study of Multiple System Atrophy in China

NCT07644013Multiple System Atrophy, Parkinson's Disease, Atypical Parkinsonism

Peking University First Hospital

Observational

214

Beijing

2025-06-01

Not yet open

Acupuncture for Painful Temporomandibular Disorder

NCT06738667Temporomandibular Disorders (TMD)

Beijing Hospital of Traditional Chinese Medicine

Not applicable

Beijing

2025-06-01

Recruiting

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

NCT07340723GVHD,Acute, Stem Cell Transplant Complications

DrugRuxolitinib

Daihong Liu

Phase 2

168

Beijing

2025-06-01

Not yet open

A Multi-Center Bidirectional Cohort Study on Total Knee Arthroplasty for the Treatment of Knee Osteoarthritis

NCT06990594Osteoarthritis

Beijing Tsinghua Chang Gung Hospital

Observational

120

Beijing

2025-06-01

Not yet open

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

NCT07007728Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver

DrugsCapeox·Lenvatinib·Bevacizumab

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-06-01

Active, closed

Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain

NCT06344403Herpes Zoster, Local Infiltration, Acute Pain

Beijing Tiantan Hospital

Not applicable

136

Beijing

2025-06-01

Recruiting

Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support Tools in the Management of Patients With "Four Highs" (Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia)

NCT07400549Hypertension, Hyperglycemia, Hyperlipidemia, Hyperuricemia

China National Center for Cardiovascular Diseases

Not applicable

100

Beijing

2025-06-01

Recruiting

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in Patients With Acute Myeloid Leukemia

NCT07537738Acute Myeloid Leukemia (AML), MLL Rearrangement

Peking University People's Hospital

Observational

210

Beijing

2025-06-01

Not yet open

Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance

NCT06986538Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection

Sixth Affiliated Hospital, Sun Yat-sen University

Not applicable

1,064

Beijing, Fuzhou, Guangzhou, Qingyuan, Shaoguan, Zhaoqing, Nanning, Guiyang

2025-06-01

Recruiting

Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

NCT07109765Hidradenitis Suppurativa (HS)

DrugSecukinumab

Peking Union Medical College

Observational

Beijing

2025-06-01

Not yet open

A Multi-Center Study on the Clinical Advantages of Personalized Total Knee Arthroplasty System

NCT07003035Osteoarthritis

YujiakuoTHU

Observational

Beijing

2025-06-01

Recruiting

A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.

NCT07679399Biliary Tract Neoplasms Immunotherapy

DrugCapecitabine

Peking Union Medical College Hospital

Phase 2

222

Beijing

2025-06-01

Not yet open

Study on the Weight Loss Effects and Mechanisms of Probiotic Preparation Intervention in Weight Cyclers

NCT07031596Obesity and Obesity-related Medical Conditions

Peking Union Medical College Hospital

Not applicable

198

Beijing

2025-06

Recruiting

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

NCT06980597Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)

Beijing GoBroad Hospital

Phase 1

Beijing

2025-06

Not yet open

Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk

NCT07010588Hepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI), Randomized Controlled Trial

Peking University People's Hospital

Not applicable

1,389

Beijing, Chongqing, Handan, Harbin, Wuhan, Changchun, Jinan, Qingdao

2025-06

Not yet open

Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation

NCT06970132Advanced Solid Tumor

Shouyao Holdings (Beijing) Co. LTD

Phase 1/2

102

Beijing

2025-06

Not yet open

Prospective Randomized Controlled Trial of VR Cognitive Training in Reducing Postoperative Delirium in Elderly Patients With Cerebral Small Vessel Disease Undergoing Non-Cardiac Surgery

NCT06999668Postoperative Delirium (POD), Cerebral Small Vessel Diseases

Peking University Third Hospital

Not applicable

416

Beijing

2025-05-31

Recruiting

The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy

NCT06765733Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy, MSA

DrugAleeto

Beijing Tiantan Hospital

Early Phase 1

Beijing

2025-05-31

Recruiting

Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND

NCT06954155Stroke

DrugTenecteplase

Beijing Tiantan Hospital

Phase 3

330

Beijing

2025-05-30

Recruiting

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

DrugOctreotide LAR

Novartis Pharmaceuticals

Phase 3

240

Beijing, Shanghai

2025-05-30

Recruiting

Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases

NCT07087873Idiopathic Inflammatory Demyelinating Disorders of the Central Nervous System, MS (Multiple Sclerosis), NMOSD, Acute Disseminated Encephalomyelitis

Xuanwu Hospital, Beijing

Not applicable

128

Beijing

2025-05-30

Not yet open

Arthroscopic Treatment of Rotator Cuff Tears

NCT06961318Rotator Cuff

Peking University Third Hospital

Observational

600

Beijing

2025-05-30

Recruiting

Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas

NCT07066982Sarcoma, Sarcoma, Kaposi, Sarcoma, Ewing, Sarcoma,Soft Tissue

Essen Biotech

Phase 1/2

Beijing

2025-05-29

Active, closed

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

NCT06970743Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsChlorambucil·Tacabrutideg·Bendamustine·Methylprednisolone

BeOne Medicines

Phase 3

153

Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shenzhen, Nanning

2025-05-29

Recruiting

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

NCT06954467Hepatocellular Carcinoma

DrugsJS007·JS207

Shanghai Junshi Bioscience Co., Ltd.

Phase 2

Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai

2025-05-29

Recruiting

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment

NCT07152288Paroxysmal Nocturnal Hemoglobinuria (PNH)

DrugHSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 1

Beijing

2025-05-29

Recruiting

Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

NCT06780098Lung Neoplasm

DrugsR-DXd·Ifinatamab Deruxtecan·Taxotere·Docetaxel

Merck Sharp & Dohme LLC

Phase 2

144

Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai

2025-05-28

Recruiting

A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）

NCT07010419NSCLC, Adjuvant Treatment

DrugFurmonertinib

Allist Pharmaceuticals, Inc.

Phase 3

338

Beijing, Guangdong

2025-05-28

Recruiting

Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease

NCT06992804Alzheimer Disease

Xuanwu Hospital, Beijing

Early Phase 1

Beijing

2025-05-28

Recruiting

Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients

NCT06395285ROSAH

DrugDF-003

Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)

Phase 1

Beijing

2025-05-27

Recruiting

Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16

NCT06410131Solid Tumors

Sound Biopharmaceuticals Ltd.

Phase 1

Beijing

2025-05-27

Recruiting

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III

NCT06971094SMA - Spinal Muscular Atrophy

GeneCradle Inc

Phase 3

Beijing, Shanghai, Shenzhen, Suzhou, Wuhan

2025-05-27

Recruiting

Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study

NCT07111364Deep Learning, Ultrasound, Bladder Cancer

Peking University First Hospital

Observational

400

Beijing

2025-05-27

Recruiting

A Phase IIa Clinical Study to Assess the Efficacy and Safety of GenSci048 in Patients With Moderate to Severe Endometriosis-Associated Pain

NCT06963177Endometriosis-related Pain

DrugGenSci048

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 2

200

Beijing

2025-05-26

Recruiting

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors

NCT06943677Advanced Malignant Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1

Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan

2025-05-26

Recruiting

Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer

NCT07267078Biliary Tract Cancer

Peking Union Medical College Hospital

Phase 2

Beijing

2025-05-25

By invitation

Mass Spectrometry-based Immune Profiling in Autoimmune Diseases

NCT07188285Systemic Lupus Erthematosus, Sjogren's Syndrome, Inflammatory Myopathies, Systemic Sclerosis (SSc)

Peking University People's Hospital

Observational

500

Beijing

2025-05-25

Active, closed

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

NCT06588153Glucocorticoid-induced Osteoporosis

DrugsProlia·Denosumab

Amgen

Phase 4

102

Beijing, Guangzhou, Shenzhen, Luoyang, Wuhan, Changzhou, Huaian, Nantong

2025-05-24

Recruiting

A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults

NCT07013097Lichen Simplex Chronicus

DrugPG-033

Prime Gene Therapeutics Co., Ltd.

Phase 1

Beijing

2025-05-23

Recruiting

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

NCT07002112Relapsed/Refractory B-cell Malignancies

The First Affiliated Hospital with Nanjing Medical University

Phase 1

Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing

2025-05-23

By invitation

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

NCT06936527Colorectal Cancer, Metastatic Colorectal Cancer With RAS Mutation

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 1/2

102

Beijing

2025-05-23

Recruiting

Liraglutide Treatment in Obese Infertile PCOS Women

NCT06742710PCOS, Obesity, Infertility

DrugMetformin

Peking University Third Hospital

Phase 4

890

Beijing

2025-05-22

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang

2025-05-22

Recruiting

Photoacoustic/Ultrasound Imaging of Brown Adipose Tissue Activity

NCT07327684Insulin Resistance, Metabolic Syndrome

Peking Union Medical College Hospital

Not applicable

100

Beijing

2025-05-22

Recruiting

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

NCT06962800Primary Membranous Nephropathy

DrugsFelzartamab·Tacrolimus

Biogen

Phase 3

180

Fuyang, Beijing, Xichengqu Beijing, Xiamen, Lanzhou, Guangzhou, Shenzhen, Nanning

2025-05-22

Recruiting

Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT

NCT06984536Myelodysplastic Syndrome, Acute Leukemia

Peking University People's Hospital

Phase 2

Beijing

2025-05-21

Recruiting

Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors

NCT06902350Neoplasms, Glioblastoma, Adult, Small Cell Lung Carcinoma (SCLC)

Chipscreen Biosciences, Ltd.

Phase 1

102

Beijing, Changchun

2025-05-21

Recruiting

Teclistamab in Previously Treated AL Amyloidosis

NCT06935162AL Amyloidosis

DrugTeclistamab

Peking Union Medical College Hospital

Phase 2

Beijing

2025-05-21

Recruiting

Use of Nasal Pressure to Assess Inspiratory Effort Under Different Oxygen Treatments

NCT06970990Critical Care, Inspiratory Effort

Jian-Xin Zhou

Not applicable

Beijing

2025-05-20

Recruiting

A Pharmacokinetics and Safety Study of Azvudine Tablets in Subjects With Mild-To-Moderate GFR Decline in Renal Insufficiency and in Healthy Subjects

NCT07001436Renal Insufficiency

DrugAzvudine

Henan Genuine Biotech Co., Ltd.

Phase 1

Beijing

2025-05-20

Recruiting

A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors

NCT07050459Locally Advanced Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1

220

Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu

2025-05-20

Recruiting

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370Heart Failure

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

4,200

Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian

2025-05-20

Recruiting

Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach

NCT06992362Hepatoid Adenocarcinoma of Stomach

Peking University Cancer Hospital & Institute

Phase 2

Beijing

2025-05-20

Not yet open

Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia

NCT06971913SLE (Systemic Lupus), CMV

DrugsGanciclovir·Aldesleukin

Peking University People's Hospital

Phase 2

100

Beijing

2025-05-20

Recruiting

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581Asthma

DrugTilrekimig

Pfizer

Phase 2

252

Beijing, Guangzhou, Baotou, Hohhot, Najing, Nanjing, Xuzhou, Nanchang

2025-05-20

Not yet open

AI-based Prediction Model of Difficult Tracheal Intubation Using Medical Image Parameters

NCT06982144Difficult Airway

Mu Dong Liang

Observational

228

Beijing

2025-05-20

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06972472Obesity, Overweight, Type 2 Diabetes

DrugOrforglipron

Eli Lilly and Company

Phase 3

600

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-19

Recruiting

Vunakizumab for the Treatment of Mild to Moderate Systemic Lupus Erythematosus

NCT06881290Lupus Erythematosus, Systemic

DrugVunakizumab

Chinese SLE Treatment And Research Group

Phase 1

Beijing

2025-05-19

Recruiting

To Evaluate the Effect of Food on the Pharmacokinetics of Y-4 Tablets in Healthy Subjects

NCT07013773Healthy Male and Female Subjects

DrugY-4

Beijing Tiantan Hospital

Phase 1

Beijing

2025-05-19

Recruiting

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

NCT06978647Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

DrugYTS109 cell

China Immunotech (Beijing) Biotechnology Co., Ltd.

Phase 1

Beijing

2025-05-19

Not yet open

Acupuncture for Anxiety and Depression

NCT06994351Anxiety and Depression, Breast Cancer Survivor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Not applicable

Beijing

2025-05-18

Recruiting

PBC Long-term Outcomes Study

NCT07149675Primary Biliary Cholangitis (PBC), Long-term Outcomes, Prognosis, Multicenter Prospective Study

Beijing Friendship Hospital

Observational

4,000

Beijing

2025-05-18

Recruiting

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

NCT06947993Atopic Dermatitis

Novartis Pharmaceuticals

Phase 2

224

Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai

2025-05-16

Recruiting

A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma

NCT07063888Intrahepatic Cholangiocarcinoma (Icc), Adjuvant Chemoradiotherapy, Narrow Margin, Lymph Node Involvement

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

Beijing

2025-05-16

Recruiting

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

NCT06969612NSCLC (Advanced Non-small Cell Lung Cancer)

DrugsGolidocitinib·Albumin paclitaxel·Pemetrexed·Tislelizumab

Peking University Cancer Hospital & Institute

Phase 1

Beijing

2025-05-15

Not yet open

Multimodal Imaging and Biospecimen Collection for Low Back Pain (LBPB)

NCT06967363Chronic Low Back Pain (CLBP), Acute Low Back Pain, Low Back Pain, Chronic Pain

Peking University Third Hospital

Observational

360

Beijing

2025-05-15

Recruiting

Drug- Eluting Stent for Symptomatic Intracranial Arterial Stenosis

NCT07197970Symptomatic Intracranial Atherosclerotic Stenosis

Beijing Tiantan Hospital

Phase 3

224

Beijing

2025-05-15

Active, closed

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

NCT06972459Obesity, Overweight

DrugOrforglipron

Eli Lilly and Company

Phase 3

800

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-15

Not yet open

AI-driven Automated Biomedical Research

NCT06962423Biomedical Research, Artificial Intelligence (AI)

Tsinghua University

Not applicable

Beijing

2025-05-15

Not yet open

SONICURE（SONICracker for the Treatment of UndeRExpansion）

NCT06924736Coronary Artery Disease

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Not applicable

200

Beijing

2025-05-15

Recruiting

Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU

NCT07391618Advanced Colorectal Cancer

Chinese PLA General Hospital

Phase 2

583

Beijing

2025-05-15

Recruiting

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

NCT07489989Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Daihong Liu

Phase 2

Beijing

2025-05-15

Active, closed

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

NCT06993792Obesity, Overweight, Type 2 Diabetes

DrugOrforglipron

Eli Lilly and Company

Phase 3

1,400

Beijing, Chengdu, Chongqing, Guangzhou, Harbin, Hefei, Jinan, Luoyang Shi

2025-05-15

Recruiting

Optimizing Reperfusion to Improve Outcomes and Neurologic Function

NCT06990867Acute Ischemic Stroke

Corxel Pharmaceuticals

Phase 2/3

740

Baotou, Beijing, Changchun, Guangzhou, Harbin, Kaili, Linfen, Nanyang

2025-05-15

Recruiting

A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma

Hangzhou DAC Biotechnology Co., Ltd.

Phase 1

110

Changsha, Hangzhou, Beijing

2025-05-15

Not yet open

A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06944496Gastric Carcinoma

DrugsDisitamab Vedotin·Tislelizumab·Capecitabine·Oxaliplatin

RemeGen Co., Ltd.

Phase 3

616

Beijing

2025-05-15

Not yet open

Evaluation of AI-Generated Clinical Advice by Physicians

NCT06980467Artificial Intelligence (AI)

Tsinghua University

Not applicable

Beijing, Wuxi

2025-05-15

Active, closed

The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer

NCT06824259Prostate Cancer

Peking University First Hospital

Not applicable

400

Beijing

2025-05-14

Recruiting

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

NCT06925737Prostate Cancer, Prostatic Neoplasms

DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel

Merck Sharp & Dohme LLC

Phase 3

1,440

Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan

2025-05-13

Recruiting

Transcutaneous Auricular Vagus Nerve Stimulation and Quality of Recovery After Major Noncardiac Surgery

NCT06957912Vagus Nerve Stimulation, Transcutaneous Electric Nerve Stimulation, Noncardiac Surgery, Quality of Recovery

Peking University First Hospital

Not applicable

320

Beijing

2025-05-13

Recruiting

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

NCT06589830Colorectal Cancer Metastatic, Advanced Colorectal Cancer

DrugTrastuzumab

Suzhou Teligene Ltd.

Phase 2

Beijing

2025-05-13

Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

NCT06819891Moderately to Severely Active Crohns Disease

DrugAfimkibart

Hoffmann-La Roche

Phase 3

425

Ganzhou, Jinhua, Beijing, Chengdu, Guangzhou, Haikou, Huai'an, Huizhou

2025-05-12

Recruiting

Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)

NCT06936176Carotid Artery Stenosis

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Not applicable

204

Beijing

2025-05-12

Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)

Acerand Therapeutics (Hong Kong) Limited

Phase 1

Beijing, Hangzhou, Shanghai, Zhengzhou, Fuzhou

2025-05-12

Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

NCT06885281Solid Tumors

DrugZL-1310

Zai Lab (Shanghai) Co., Ltd.

Phase 1/2

166

Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai

2025-05-12

Recruiting

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

NCT06929299Primary Immune Thrombocytopenia (ITP)

Jiangsu BioJeTay Biotechnology Co., Ltd.

Phase 1/2

Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin

2025-05-12

Recruiting

Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)(Extended Follow-Up)

NCT06936189Carotid Artery Stenosis

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Observational

204

Beijing

2025-05-12

Recruiting

Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer

NCT07353684Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach

DrugsApatinib·Adebrelimab

Beijing Friendship Hospital

Phase 2

Beijing

2025-05-11

Active, closed

Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects

NCT07054034Bronchial Asthma

Shanghai Mabgeek Biotech.Co.Ltd

Phase 2

160

Beijing

2025-05-11

Not yet open

Evaluation of the Safety and Efficacy of Artificial Bone Repair Materials for Repair of Long Bone Defects in the Extremities

NCT06959459Bone Defects of the Limbs

Chinese PLA General Hospital

Not applicable

156

Beijing

2025-05-10

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=5

Query this register directly

GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,576 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,389 of the 5,576 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 990 have not yet opened recruitment, 1,019 are active but closed to new participants, and 178 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.